Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Cash & Equivalents (2021 - 2025)

Zymeworks' Cash & Equivalents history spans 5 years, with the latest figure at $41.2 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 37.74% to $41.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $41.2 million, a 37.74% decrease, with the full-year FY2025 number at $41.2 million, down 37.74% from a year prior.
  • Cash & Equivalents hit $41.2 million in Q4 2025 for Zymeworks, down from $64.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for ZYME hit a ceiling of $400.9 million in Q4 2022 and a floor of $41.2 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $128.6 million across 5 years, with a median of $98.3 million in 2025.
  • Biggest five-year swings in Cash & Equivalents: soared 98.6% in 2022 and later tumbled 60.7% in 2023.
  • Tracing ZYME's Cash & Equivalents over 5 years: stood at $201.9 million in 2021, then soared by 98.6% to $400.9 million in 2022, then tumbled by 60.7% to $157.6 million in 2023, then plummeted by 58.05% to $66.1 million in 2024, then crashed by 37.74% to $41.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for ZYME at $41.2 million in Q4 2025, $64.8 million in Q3 2025, and $98.3 million in Q2 2025.